X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ASTRAZENECA PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. ASTRAZENECA PHARMA FRESENIUS KABI ONCO./
ASTRAZENECA PHARMA
 
P/E (TTM) x 22.1 104.8 21.1% View Chart
P/BV x 3.1 14.9 20.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ASTRAZENECA PHARMA
Mar-14
FRESENIUS KABI ONCO./
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1761,285 13.7%   
Low Rs79634 12.4%   
Sales per share (Unadj.) Rs37.7189.6 19.9%  
Earnings per share (Unadj.) Rs5.1-0.2 -2,501.6%  
Cash flow per share (Unadj.) Rs6.73.8 174.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.568.6 62.0%  
Shares outstanding (eoy) m158.2325.00 632.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.45.1 66.7%   
Avg P/E ratio x25.0-4,712.7 -0.5%  
P/CF ratio (eoy) x18.9249.6 7.6%  
Price / Book Value ratio x3.014.0 21.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,13523,988 83.9%   
No. of employees `0001.21.6 73.9%   
Total wages/salary Rs m7031,605 43.8%   
Avg. sales/employee Rs Th5,176.23,040.2 170.3%   
Avg. wages/employee Rs Th610.41,029.2 59.3%   
Avg. net profit/employee Rs Th699.6-3.3 -21,426.8%   
INCOME DATA
Net Sales Rs m5,9634,740 125.8%  
Other income Rs m1892 19.5%   
Total revenues Rs m5,9814,832 123.8%   
Gross profit Rs m1,430-130 -1,101.8%  
Depreciation Rs m258101 254.8%   
Interest Rs m-260-   
Profit before tax Rs m1,216-139 -875.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68139 -49.0%   
Tax Rs m3425 6,723.0%   
Profit after tax Rs m806-5 -15,833.0%  
Gross profit margin %24.0-2.7 -875.7%  
Effective tax rate %28.1-3.7 -767.8%   
Net profit margin %13.5-0.1 -12,584.9%  
BALANCE SHEET DATA
Current assets Rs m5,1022,726 187.1%   
Current liabilities Rs m2,3852,435 98.0%   
Net working cap to sales %45.66.1 740.9%  
Current ratio x2.11.1 191.0%  
Inventory Days Days15074 203.4%  
Debtors Days Days11341 277.9%  
Net fixed assets Rs m5,1481,035 497.3%   
Share capital Rs m15850 316.4%   
"Free" reserves Rs m6,556942 695.6%   
Net worth Rs m6,7321,716 392.3%   
Long term debt Rs m9520-   
Total assets Rs m10,3884,156 250.0%  
Interest coverage x-45.8NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.1 50.3%   
Return on assets %7.5-0.1 -6,130.1%  
Return on equity %12.0-0.3 -4,036.0%  
Return on capital %14.60-  
Exports to sales %74.55.7 1,306.3%   
Imports to sales %24.86.5 383.4%   
Exports (fob) Rs m4,441270 1,643.4%   
Imports (cif) Rs m1,477306 482.3%   
Fx inflow Rs m5,298375 1,414.2%   
Fx outflow Rs m1,772470 376.9%   
Net fx Rs m3,525-96 -3,689.6%   
CASH FLOW
From Operations Rs m1,274-8 -15,729.6%  
From Investments Rs m-1,204-146 826.5%  
From Financial Activity Rs m-196862 -22.7%  
Net Cashflow Rs m-126709 -17.8%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 75.0 108.0%  
Indian inst/Mut Fund % 0.3 0.3 100.0%  
FIIs % 9.6 15.7 61.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 9.1 100.0%  
Shareholders   42,599 12,856 331.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - SHASUN PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS